Descartes 25
Alternative Names: Descartes-25Latest Information Update: 28 Nov 2024
Price :
$50 *
At a glance
- Originator Cartesian Therapeutics
- Class Antineoplastics; Gene therapies; Immunotherapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Multiple myeloma
- Phase I Autoimmune disorders
- Preclinical Cancer
Most Recent Events
- 08 Nov 2024 Cartesian Therapeutics terminates the phase I/II trial in Multiple myeloma (Refractory metastatic disease, Second-line therapy or greater) in USA (Parenteral) (NCT05113342)
- 03 Jul 2023 Phase-I clinical trials in Autoimmune disorders (Parenteral) (Cartesian Therapeutics pipeline, July 2023)
- 25 Jan 2022 Pharmacodynamics data from preclinical studies in Multiple myeloma released by Cartesian Therapeutics